Intelligence Report · ~12 min read
Orbit Pharma Limited Intelligence Report
Generated from 1 signals · 3 evidence sources
Type
Company Intelligence ReportGenerated
Jun 21, 2026
Confidence
Moderate Confidence · 72%
Evidence
6 items
Sources
7
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Orbit Pharma Limited maintains an active intelligence profile across Neurology, Antiemetic. 1 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with low portfolio impact. Evidence coverage stands at 72% across 3 tracked sources. Highest-priority development: FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG). Regulatory precedent. Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Orbit Pharma Limited.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Hubei Gedian Humanwell Pharmaceutical Co., Ltd. - 725591 - 06/03/2026
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Macau-Union Pharmaceutical Limited - 724506 - 05/29/2026
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
Regulatory precedent may inform portfolio positioning
View detail - regulatory
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 17 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: Low.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceHubei Gedian Humanwell Pharmaceutical Co., Ltd. - 725591 - 06/03/2026
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceMacau-Union Pharmaceutical Limited - 724506 - 05/29/2026
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceClass 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: MHRA, MHRA, Regunera
View evidenceS6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Orbit Pharma recalls Cyclizine Lactate due to GMP deficiencies
Neurology · Antiemetic